Literature DB >> 21768

Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.

T R Bates, H P Blumenthal, H J Pieniaszek.   

Abstract

The concentrations of sulfapyridine (SP) and N4-acetylsulfapyridine (AcSP) in the plasma and saliva of 5 healthy male adults (3 slow and 2 rapid acetylators) were determined as a function of time after a single 2.0-gm oral dose of sulfasalazine (salicylazosulfapyridine). SP absorption commenced 3.5 to 6 hr after sulfasalazine administration and occurred slowly (apparent absorption t1/2s ranged from 1.6 to 5 hr) irrespective of acetylator phenotype. Appreciable differences existed between slow and rapid acetylators with respect to the biologic t1/2 and total body clearance of SP. SP concentrations in the saliva correlated well with those in the plasma. The saliva:plasma concentration ratio for SP was 0.559 +/- 0.027 (mean of 5 subjects +/- SE) and was dependent of plasma concentration and saliva pH. The mean saliva:plasma concentration ratio for AcSP was lower (0.246 +/- 0.056), consistent with the pH-partition hypothesis, and showed considerably more intrasubject and intersubject variation than the ratio for SP. These findings suggest that measurement of SP concentrations in the saliva may be a convenient, noninvasive method for monitoring indirectly the steady-state plasma (serum) concentrations of SP in patients with ulcerative colitis or Crohn's disease who are receiving sulfasalazine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 21768     DOI: 10.1002/cpt1977226917

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  Pharmacokinetics of sulfasalazine metabolites in rats following concomitant oral administration of riboflavin.

Authors:  V S Chungi; L W Dittert; L Shargel
Journal:  Pharm Res       Date:  1989-12       Impact factor: 4.200

3.  Azo reduction of sulphasalazine in healthy volunteers.

Authors:  J B Houston; J Day; J Walker
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

4.  Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.

Authors:  M E Sharp; S M Wallace; K W Hindmarsh; M A Brown
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.

Authors:  J M Day; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

7.  Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.

Authors:  J J Lima; D R Conti; A L Goldfarb; W J Tilstone; L H Golden; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

8.  The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.

Authors:  A J Taggart; B J McDermott; S D Roberts
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

9.  Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.

Authors:  T B Vree; W J O'Reilly; Y A Hekster; J E Damsma; E van der Kleijn
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.